Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge

Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against challenge. Follow up experiments indicated that pa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antiviral Res
Autors principals: Calvo-Pinilla, Eva, de la Poza, Francisco, Gubbins, Simon, Mertens, Peter Paul Clement, Ortego, Javier, Castillo-Olivares, Javier
Format: Artigo
Idioma:Inglês
Publicat: The Authors. Published by Elsevier B.V. 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7125940/
https://ncbi.nlm.nih.gov/pubmed/25643968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2015.01.009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars